/f/125658/7246x3240/f72d1f6fc5/esc-logo-lock-up-red-pos-rgb.png){kind=logo}
Discovery and in vivo evaluation of novel inhibitors of the hydrolytic activity of mitochondrial F1Fo ATP synthase to alleviate myocardial ischemia reperfusion injury
Event: ESC Congress 2023
Topic: Ischaemia, Infarction, Cardioprotection
Session: Ischaemia reperfusion
Empagliflozin restores the deregulated cardiac endothelial cell transcriptome in vivo upon myocardial ischemia reperfusion injury and reduces the infiltration of immune cells.
Event: ESC Congress 2023
Topic: Ischaemia, Infarction, Cardioprotection
Session: Ischaemia reperfusion
Cardiotoxicity in light chain amyloidosis: Insights from the first murine model with intramyocardial injection of patient-derived amyloidogenic light chains
Event: ESC Congress 2023
Topic: Pathophysiology and Mechanisms
Session: Elucidating basic mechanisms in heart failure
Cardioprotection by selective SGLT2 inhibitors in a non-diabetic mouse model of myocardial ischemia/reperfusion injury: a class or a drug effect?
Event: ESC Congress 2022
Topic: Ischaemia, Infarction, Cardioprotection
Session: Myocardial ischaemia and protective mechanisms
Understanding the molecular mosaic of cardiotoxicity of light chains in plasma cell dyscrasias and cardiac light chain amyloidosis with the use of patient derived full-length light chains
Event: ESC Congress 2022
Topic: Cardiomyopathies
Session: Cardiomyopathies
Empagliflozin rescues primary murine cardiac fibroblasts, but not cardiomyocytes, from hypoxia-reoxygenation injury through STAT3-mediated cascades.
Event: ESC Congress 2022
Topic: Antidiabetic Pharmacotherapy
Session: Anti-diabetic pharmacotherapy in clinical practice
Al amyloidosis with cardiac involvement: cardiotoxicity of aggregation prone peptides deriving from variable domains of immunoglobulin light chains
Event: ESC Congress 2020
Topic: Cardiotoxicity of Drugs and Other Therapies
Session: Mechanisms of Heart Failure and Implications for Clinical Translation
Hydrolytic activity of mitochondrial F1Fo ATP synthase as a target for myocardial ischemia: discovery and in vitro evaluation of novel inhibitors
Event: ESC Congress 2020
Topic: Mitochondria
Session: Mitochondria and Metabolism in Cardiovascular Disease
Investigating the impact of aging and hyperlipidaemia on metformin cardioprotection against carfilzomib-induced cardiotoxicity in vivo
Event: ESC Congress 2020
Topic: Cardiotoxicity of Drugs
Session: Pharmacology and Pharmacotherapy ePosters
Chronic administration of Empagliflozin induces cardioprotection in vivo in absence of diabetes mellitus
Event: ESC Congress 2019
Topic: Antidiabetic Pharmacotherapy
Session: Mechanisms underlying pharmacotherapy
ESC 365 is supported by
